A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer

Anca Chelariu-Raicu, Alpa Nick, Renata Urban, Mary Gordinier, Carola Leuschner, Linda Bavisotto, Graziela Zibetti Dal Molin, John K. Whisnant, Robert L. Coleman

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Fingerprint

Dive into the research topics of 'A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences